Armory was conceived and patented within the University of Cincinnati's business incubator and accelerator program by Dr. Jack Rubinstein, a Board-Certified cardiologist and research scientist specializing in cardiology. Dr. Rubinstein's clinical expertise and research focus led to a groundbreaking discovery inspired by the Jewish prayer practice of wearing tefillin. His studies revealed that tefillin has a cardioprotective effect by inducing a process known as Remote Ischemic Preconditioning (RIPC), which helps protect the heart from ischemic damage by triggering protective mechanisms in distant tissues.
This innovative concept was further developed into a commercial product named Armory after the technology and patent were acquired from the accelerator program. Armory represents a novel approach to cardiovascular health, leveraging the principles of RIPC to potentially reduce heart attack damage and improve cardiac outcomes.